Supplementary Table S3 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

Bruna Pellini; Russell William Madison; Merrida A. Childress; Shoshana T. Miller; Ole V. Gjoerup; Jason Cheng; Richard S.P. Huang; Michael R. Krainock; Pratyush Gupta; Wei Zou; David S. Shames; Solomon Moshkevich; Marcus Ballinger; MC Liu; Amanda G. Young; Minu K. Srivastava; Geoffrey R. Oxnard; Mark A. Socinski

doi:10.1158/1078-0432.31084987

Supplementary Table S3 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

2026 Open access

Read full text

Authors: Bruna Pellini, Russell William Madison, Merrida A. Childress, Shoshana T. Miller, Ole V. Gjoerup, Jason Cheng, Richard S.P. Huang, Michael R. Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich

+6 more

Marcus Ballinger, MC Liu, Amanda G. Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski

DOI: 10.1158/1078-0432.31084987

Cited by: 0

Abstract

ctDNA decrease from any subsequent cycle was associated with greater objective response in patients treated with chemoIO. Number of patients per best objective response with associated increase or decreases in ctDNA levels between subsequent cycles.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Publication date: 19 January 2026